Olaparib治疗携带DNA修复基因异常的转移性去势抵抗性前列腺癌(TOPARP-B):一项多中心、开放标签、随机2期试验
TOPARP-B是一项在英国17家医院开展的开放标签、随机2期试验,采用选择设计,入组既往接受过1–2线紫杉类化疗、ECOG评分≤2的转移性去势抵抗性前列腺癌患者,经靶向测序检出DDR基因异常者按1:1随机接受400 mg或300 mg olaparib每日两次。
要点
- 两组最常见3–4级不良事件均为贫血(300 mg组31%、400 mg组37%)。
- 结果支持临床对mCRPC实施基因组分层以筛选olaparib获益人群。
核心结论
- Olaparib对携带DDR基因异常的转移性去势抵抗性前列腺癌具有抗肿瘤活性。
- 研究支持在临床实践中对转移性去势抵抗性前列腺癌实施基因组分层。
研究设计与样本
- 开放标签、研究者发起的随机2期试验,采用选择(pick-the-winner)设计,来自英国17家医院。
- 入组18岁及以上、既往接受过1或2线紫杉类化疗、ECOG评分≤2的进展期mCRPC患者,肿瘤活检行靶向测序。
- 检出DDR基因异常者按1:1随机分配至olaparib 400 mg或300 mg每日两次,连续给药,4周为一周期,直至疾病进展或不可耐受毒性。
- 随机采用计算机生成的最小化法,并按筛查时循环肿瘤细胞计数平衡;受试者与研究者均未设盲。
- 711例患者同意靶向筛查,161例检出DDR基因异常,98例随机并接受治疗(每个剂量组49例),92例可评估主要终点(每组46例)。
关键数值与推荐
- 每个组分需在至少4周后的连续评估中确认。
- 若某剂量队列44例可评估患者中至少19例(43%)缓解,则该剂量队列视为成功。
- 安全性在所有接受至少一剂olaparib的患者中评估。
临床怎么用
- 对mCRPC患者可考虑肿瘤活检行DDR基因靶向测序,以筛选可能从olaparib治疗中获益者。
- 400 mg每日两次方案的确认复合缓解率数值上高于300 mg组,但研究未设盲且非直接比较优效性。
- 治疗期间需监测贫血等3–4级不良事件。
局限性
- 开放标签设计,受试者与研究者均未设盲。
- 样本量小,每个剂量组仅49例接受治疗、46例可评估主要终点。
- 研究未设计用于两种剂量间的正式优效性比较。
- 入组人群限于既往接受过1–2线紫杉类化疗且ECOG评分≤2者,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and response to olaparib in metastatic castration-resistant prostate cancer. METHODS: In this open-label, investigator-initiated, randomised phase 2 trial following a selection (or pick-the-winner) design, we recruited participants from 17 UK hospitals. Men aged 18 years or older with progressing metastatic castration-resistant prostate cancer previously treated with one or two taxane chemotherapy regimens and with an Eastern Cooperative Oncology Group performance status of 2 or less had tumour biopsies tested with targeted sequencing. Patients with DDR gene aberrations were randomly assigned (1:1) by a computer-generated minimisation method, with balancing for circulating tumour cell count at screening, to receive 400 mg or 300 mg olaparib twice daily, given continuously in 4-week cycles until disease progression or unacceptable toxicity. Neither participants nor investigators were masked to dose allocation. The primary endpoint of confirmed response was defined as a composite of all patients presenting with any of the following outcomes: radiological objective response (as assessed by Response Evaluation Criteria in Solid Tumors 1.1), a decrease in prostate-specific antigen (PSA) of 50% or more (PSA50) from baseline, or conversion of circulating tumour cell count (from ≥5 cells per 7·5 mL blood at baseline to <5 cells per 7·5 mL blood). A confirmed response in a consecutive assessment after at least 4 weeks was required for each component. The primary analysis was done in the evaluable population. If at least 19 (43%) of 44 evaluable patients in a dose cohort responded, then the dose cohort would be considered successful. Safety was assessed in all patients who received at least one dose of olaparib. This trial is registered at ClinicalTrials.gov, NCT01682772. Recruitment for the trial has completed and follow-up is ongoing. FINDINGS: 711 patients consented for targeted screening between April 1, 2015, and Aug 30, 2018. 161 patients had DDR gene aberrations, 98 of whom were randomly assigned and treated (49 patients for each olaparib dose), with 92 evaluable for the primary endpoint (46 patients for each olaparib dose). Median follow-up was 24·8 months (IQR 16·7-35·9). Confirmed composite response was achieved in 25 (54·3%; 95% CI 39·0-69·1) of 46 evaluable patients in the 400 mg cohort, and 18 (39·1%; 25·1-54·6) of 46 evaluable patients in the 300 mg cohort. Radiological response was achieved in eight (24·2%; 11·1-42·3) of 33 evaluable patients in the 400 mg cohort and six (16·2%; 6·2-32·0) of 37 in the 300 mg cohort; PSA50 response was achieved in 17 (37·0%; 23·2-52·5) of 46 and 13 (30·2%; 17·2-46·1) of 43; and circulating tumour cell count conversion was achieved in 15 (53·6%; 33·9-72·5) of 28 and 13 (48·1%; 28·7-68·1) of 27. The most common grade 3-4 adverse event in both cohorts was anaemia (15 [31%] of 49 patients in the 300 mg cohort and 18 [37%] of 49 in the 400 mg cohort). 19 serious adverse reactions were reported in 13 patients. One death possibly related to treatment (myocardial infarction) occurred after 11 days of treatment in the 300 mg cohort. INTERPRETATION: Olaparib has antitumour activity against metastatic castration-resistant prostate cancer with DDR gene aberrations, supporting the implementation of genomic stratification of metastatic castration-resistant prostate cancer in clinical practice. FUNDING: Cancer Research UK, AstraZeneca, Prostate Cancer UK, the Prostate Cancer Foundation, the Experimental Cancer Medicine Centres Network, and the National Institute for Health Research Biomedical Research Centres.
引用
- Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2019. PMID: 31806540. doi:10.1016/S1470-2045(19)30684-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。